AR051429A1 - Composicion farmaceutica ozonizada y metodos para obtenerla - Google Patents

Composicion farmaceutica ozonizada y metodos para obtenerla

Info

Publication number
AR051429A1
AR051429A1 ARP040101321A ARP040101321A AR051429A1 AR 051429 A1 AR051429 A1 AR 051429A1 AR P040101321 A ARP040101321 A AR P040101321A AR P040101321 A ARP040101321 A AR P040101321A AR 051429 A1 AR051429 A1 AR 051429A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
ozonized
methods
allow
topical treatment
Prior art date
Application number
ARP040101321A
Other languages
English (en)
Original Assignee
Stenti De Pirillo Haydee A
Pirillo Claudia Fernanda
Pastoriza Jose Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stenti De Pirillo Haydee A, Pirillo Claudia Fernanda, Pastoriza Jose Maria filed Critical Stenti De Pirillo Haydee A
Priority to ARP040101321A priority Critical patent/AR051429A1/es
Priority to BRPI0509989-7A priority patent/BRPI0509989A2/pt
Priority to EP05777686A priority patent/EP1765373A4/en
Priority to MXPA06012206A priority patent/MXPA06012206A/es
Priority to NZ550671A priority patent/NZ550671A/en
Priority to CA002563697A priority patent/CA2563697A1/en
Priority to AU2005249370A priority patent/AU2005249370B2/en
Priority to PCT/US2005/013223 priority patent/WO2005117913A2/en
Priority to US11/568,155 priority patent/US20070254963A1/en
Publication of AR051429A1 publication Critical patent/AR051429A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica para el tratamiento topico de diversas afecciones en humanos y animales, que combina aceites ozonizados con metilsulfonilmetano (MSM) y dimetilsulfoxido (DMSO) para permitir una mayor penetracion de los principios activos y de esta manera permitir el tratamiento topico de enfermedades externas como internas.
ARP040101321A 2004-04-20 2004-04-20 Composicion farmaceutica ozonizada y metodos para obtenerla AR051429A1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ARP040101321A AR051429A1 (es) 2004-04-20 2004-04-20 Composicion farmaceutica ozonizada y metodos para obtenerla
BRPI0509989-7A BRPI0509989A2 (pt) 2004-04-20 2005-04-20 composição farmacêutica para uso em aplicação tópica para tratar doenças em seres humanos e animais, e, método para obter a mesma
EP05777686A EP1765373A4 (en) 2004-04-20 2005-04-20 OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
MXPA06012206A MXPA06012206A (es) 2004-04-20 2005-04-20 Composicion farmaceutica ozonizada y metodos.
NZ550671A NZ550671A (en) 2004-04-20 2005-04-20 Ozonised pharmaceutical composition and method
CA002563697A CA2563697A1 (en) 2004-04-20 2005-04-20 Ozonized pharmaceutical composition and method
AU2005249370A AU2005249370B2 (en) 2004-04-20 2005-04-20 Ozonized pharmaceutical composition and method
PCT/US2005/013223 WO2005117913A2 (en) 2004-04-20 2005-04-20 Ozonized pharmaceutical composition and method
US11/568,155 US20070254963A1 (en) 2004-04-20 2005-04-20 Ozonidzed Pharmaceutical Composition and Method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040101321A AR051429A1 (es) 2004-04-20 2004-04-20 Composicion farmaceutica ozonizada y metodos para obtenerla

Publications (1)

Publication Number Publication Date
AR051429A1 true AR051429A1 (es) 2007-01-17

Family

ID=37461286

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101321A AR051429A1 (es) 2004-04-20 2004-04-20 Composicion farmaceutica ozonizada y metodos para obtenerla

Country Status (9)

Country Link
US (1) US20070254963A1 (es)
EP (1) EP1765373A4 (es)
AR (1) AR051429A1 (es)
AU (1) AU2005249370B2 (es)
BR (1) BRPI0509989A2 (es)
CA (1) CA2563697A1 (es)
MX (1) MXPA06012206A (es)
NZ (1) NZ550671A (es)
WO (1) WO2005117913A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
ITBS20070178A1 (it) * 2007-11-15 2009-05-16 Paoli Ambrosi Gianfranco De Composizione per uso farmaceutico e/o cosmetico e/o in forma di dispositivo medico per favorire processi di cicatrizzazione, per il trattamento di cicatrici ipertrofiche e per migliorare le proprieta' biomeccaniche della cute
EP2493314B1 (en) 2009-10-30 2020-04-08 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
ITMI20110354A1 (it) * 2011-03-07 2012-09-08 Neovalis S R L Composizione a base di olio ozonizzato per uso topico
DE102011013920A1 (de) * 2011-03-14 2012-09-20 Wolfgang Winkelmann Medizinische Hautabdeckung zur Behandlung von Infektionen der Haut
DE102012007239A1 (de) * 2012-04-10 2013-10-10 Wolfgang Winkelmann Pharmazeutische Zusammensetzung enthaltend eine mit Sauerstoff angereicherte ungesättigte Fettsäure und ein organisches Lösungsmittel
DE102015001289A1 (de) * 2015-01-29 2016-08-04 Wolfgang Winkelmann Pharmazeutische Zusammensetzungen und Pflanzenschutzmittel enthaltend mit Sauerstoff angereicherte Pflanzenöle oder Fettsäuren
RU2627465C2 (ru) * 2015-09-30 2017-08-08 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт фтизиопульмонологии" Министерства здравоохранения Российской Федерации (ФГБУ "УНИИФ" Минздрава России) Способ обработки костной полости после некрсеквестрэктомии

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477469A (en) * 1979-08-30 1984-10-16 Herschler R J Preparations containing methylsulfonylmethane and methods of use and purification
US4296130A (en) * 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
US4591602A (en) * 1982-04-16 1986-05-27 James H. Brown Ozonide esters and topical compositions containing same
US4451480A (en) * 1982-04-16 1984-05-29 James Howard Brown Method of treating acne using ozonized materials
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US6663874B2 (en) * 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
CA2556437A1 (en) * 2004-02-20 2005-09-09 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of viral diseases

Also Published As

Publication number Publication date
WO2005117913A2 (en) 2005-12-15
EP1765373A4 (en) 2011-01-19
AU2005249370A1 (en) 2005-12-15
BRPI0509989A2 (pt) 2012-05-29
WO2005117913A3 (en) 2006-03-16
NZ550671A (en) 2009-06-26
US20070254963A1 (en) 2007-11-01
AU2005249370B2 (en) 2010-10-28
CA2563697A1 (en) 2005-12-15
EP1765373A2 (en) 2007-03-28
MXPA06012206A (es) 2007-05-16

Similar Documents

Publication Publication Date Title
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
UY30761A1 (es) Derivados de 2.3-dihidroimidazo(1,2-c) quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogénesis
UY31539A1 (es) Agentes antelminticos y su uso
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
UY32502A (es) Agentes antihelmínticos y su utilización
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
GT200500310A (es) Compuestos organicos
MXPA06012206A (es) Composicion farmaceutica ozonizada y metodos.
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
GT200600077A (es) Imidazoles sustituidos con heterociclilamida
CR11823A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
CO6450623A2 (es) Parasiticidas sanguineos
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação

Legal Events

Date Code Title Description
FB Suspension of granting procedure